Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
1. A composition comprising:
(i) a solid amorphous form of Compound 1,
wherein the solid amorphous form has:
(a) a mid-point temperature of a glass transition temperature of about 79.7° C.; and
(b) an enantiomeric excess value of at least 97%; and
(ii) a crystalline form of Compound 1, wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 16.4±0.2° and 21.4±0.2°.
2. The composition of claim 1 , wherein the crystalline form has a melting point onset temperature of 139±2° C.
3. The composition of claim 1 , wherein the crystalline form has an enantiomeric excess value of at least 45%.
4. The composition of claim 1 , wherein the crystalline form has a purity of at least 99.3%.
5. The composition of claim 1 , wherein the crystalline form has a purity of at least 99.5%.
6. The composition of claim 1 , wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 15.6±0.2°, 16.4±0.2°, and 21.4±0.2°.
7. The composition of claim 1 , wherein the crystalline form of Compound 1 is present in about 95% by weight of the composition.
8. The composition of claim 1 , wherein the crystalline form of Compound 1 is present in about 99% by weight of the composition.